Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials
Dermatology · 2025
DOI: 10.1159/000545148 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Dermatology, 2025. Verfasst von Niamh Kearney und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, St. Vincent's University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Psoriasis is associated with an increased risk of cardiovascular disease (CVD). Previous studies have found that treatment with tumour necrosis factor or interleukin (IL)-17 inhibitors leads to reductions in the systemic inflammation biomarkers neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR). The primary aim of this study was to evaluate changes in NLR, PLR and MLR with guselkumab compared with placebo (VOYAGE I/II), adalimumab (VOYAGE I/II), and secukinumab (ECLIPSE). The secondary aims were to assess correlation with disease severity, C-reactive protein (CRP) levels, and treatment response.
Methods
This was a post hoc analysis of VOYAGE I, VOYAGE II, and ECLIPSE Phase III randomised trial data on guselkumab for moderate-to-severe plaque psoriasis. NLR, PLR, and MLR were evaluated at baseline and Week 16 in VOYAGE I and II and at baseline and Week 12 in ECLIPSE. Mean changes were compared between groups using a Student’s t test; Pearson’s test was used for correlation analyses.
Results
VOYAGE I included 837 randomised patients, VOYAGE II included 992 randomised patients, and ECLIPSE included 1,048 randomised patients. In VOYAGE I, NLR (p = 0.011), PLR (p = 0.015), and MLR (p = 0.004) decreased significantly following 16 weeks of guselkumab treatment vs. placebo. In VOYAGE II, reductions in NLR (p = 0.003), PLR (p = 0.006), and MLR (p = 0.001) were greater at Week 16 in patients treated with guselkumab vs. placebo. Treatment with adalimumab was associated with a greater reduction (p < 0.001) in the three biomarkers vs. guselkumab, while secukinumab resulted in a similar reduction in NLR, PLR, and MLR compared with guselkumab (p = 0.413, 0.650, and 0.498, respectively). All biomarkers weakly correlated with Psoriasis Area and Severity Index (PASI) at baseline and showed modest correlations with CRP levels. Biomarkers in patients who were PASI90 responders were consistent between all active treatment groups at baseline.
Conclusions
Guselkumab is a highly efficacious treatment for plaque psoriasis; the study has demonstrated the potential benefit of treatment with guselkumab in reducing systemic inflammation as measured by NLR, PLR, and MLR, which appeared to be independent of psoriasis response, suggesting that reducing systemic inflammation with guselkumab may decrease CVD risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, St. Vincent's University Hospital, Dublin, Ireland.
- Janssen-Cilag Ltd, High Wycombe, UK.
- Valos, Johnson and Johnson Partner CRO, Genoa, Italy.
- Janssen Pharmaceutica NV, Beerse, Belgium.
- Janssen Research and Development, LLC, Spring House, Pennsylvania, USA.
- Department of Dermatology and Division of Rheumatology, UT Southwestern Medical Center, Dallas, Texas, USA.
Zitieren
APA
Kearney, N., Gorecki, P., Acciarri, L., Buyze, J., Akawung, A., Merola, J. F., & Kirby, B. (2025). Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials. Dermatology. https://doi.org/10.1159/000545148
Vancouver
Kearney N, Gorecki P, Acciarri L, Buyze J, Akawung A, Merola JF, et al. Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials. Dermatology. 2025. doi:10.1159/000545148
BibTeX
@article{Kearney2025,
author = {Kearney, Niamh and Gorecki, Patricia and Acciarri, Lorenzo and Buyze, Jozefien and Akawung, Alianu and Merola, Joseph F and Kirby, Brian},
title = {Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials},
journal = {Dermatology},
year = {2025},
doi = {10.1159/000545148}
}
EUVIMED